靶向活化血小板的CD39减轻脓毒症全身炎症并改善生存:一项临床前初步研究
该临床前初步研究在体外炎症条件下及小鼠脂多糖诱导脓毒症模型中评估血小板-白细胞-内皮相互作用,并在盲肠结扎穿刺多微生物脓毒症模型中评估结局。具有核苷三磷酸水解酶活性的药物可减少血小板-白细胞-内皮相互作用、促炎细胞因子转录、微血管血小板-中性粒细胞聚集体隔离、活化标志物表达、白细胞外渗及器官损伤。targ-CD39对这些变量的效果最强,且与nontarg-CD39和马铃薯腺苷三磷酸双磷酸酶不同,保留了止血功能。最重要的是,targ-CD39在盲肠结扎穿刺模型中改善生存的程度强于nontarg-CD39和马铃薯腺苷三磷酸双磷酸酶。作者认为靶向活化血小板的CD39是减轻脓毒症全身炎症和死亡率的有前景的新治疗概念,值得进一步开发至临床应用。
要点
- 在脓毒症条件下,具有核苷三磷酸水解酶活性的药物可减少血小板-白细胞-内皮相互作用及促炎细胞因子转录。
- targ-CD39对减少微血管血小板-中性粒细胞聚集体隔离、活化标志物表达、白细胞外渗和器官损伤的效果最强。
- 与nontarg-CD39和马铃薯腺苷三磷酸双磷酸酶不同,targ-CD39保留了止血功能。
- 在盲肠结扎穿刺模型中,targ-CD39改善生存的程度强于nontarg-CD39和马铃薯腺苷三磷酸双磷酸酶。
- 作者认为靶向活化血小板的CD39是减轻脓毒症全身炎症和死亡率的有前景的新治疗概念,值得进一步开发至临床应用。
适用人群与场景
- 人类真皮微血管内皮细胞1、人类血小板和中性粒细胞,以及C57BL/6NCrl小鼠。
- 体外为炎症条件下的血小板-白细胞-内皮相互作用评估;体内为小鼠脂多糖诱导脓毒症模型和盲肠结扎穿刺多微生物脓毒症模型。
研究设计与关键结果
- 研究类型为实验动物研究和细胞培养研究,在大学实验室内进行。
- 在脓毒症条件下,具有核苷三磷酸水解酶活性的药物减少了血小板-白细胞-内皮相互作用、促炎细胞因子转录、微血管血小板-中性粒细胞聚集体隔离、聚集体中血小板和中性粒细胞的活化标志物表达、白细胞外渗及器官损伤。
- targ-CD39对这些变量的效果最强,且与nontarg-CD39和马铃薯腺苷三磷酸双磷酸酶不同,保留了止血功能。
- 在盲肠结扎穿刺模型中,targ-CD39改善生存的程度强于nontarg-CD39和马铃薯腺苷三磷酸双磷酸酶。
证据类型、等级与局限
- 证据类型:临床前初步研究(实验动物研究和细胞培养研究)。
- 作者结论:靶向活化血小板的CD39是减轻脓毒症全身炎症和死亡率的有前景的新治疗概念,值得进一步开发至临床应用。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为靶向活化血小板的CD39是减轻脓毒症全身炎症和死亡率的有前景的新治疗概念,值得进一步开发至临床应用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Sepsis is associated with a systemic inflammatory reaction, which can result in a life-endangering organ dysfunction. Pro-inflammatory responses during sepsis are characterized by increased activation of leukocytes and platelets, formation of platelet-neutrophil aggregates, and cytokine production. Sequestration of platelet-neutrophil aggregates in the microvasculature contributes to tissue damage during sepsis. At present no effective therapeutic strategy to ameliorate these events is available. In this preclinical pilot study, a novel anti-inflammatory approach was evaluated, which targets nucleoside triphosphate hydrolase activity toward activated platelets via a recombinant fusion protein combining a single-chain antibody against activated glycoprotein IIb/IIIa and the extracellular domain of CD39 (targ-CD39).
DESIGN: Experimental animal study and cell culture study.
SETTING: University-based experimental laboratory.
SUBJECTS: Human dermal microvascular endothelial cells 1, human platelets and neutrophils, and C57BL/6NCrl mice.
INTERVENTIONS: Platelet-leukocyte-endothelium interactions were evaluated under inflammatory conditions in vitro and in a murine lipopolysaccharide-induced sepsis model in vivo. The outcome of polymicrobial sepsis was evaluated in a murine cecal ligation and puncture model. To evaluate the anti-inflammatory potential of activated platelet targeted nucleoside triphosphate hydrolase activity, we employed a potato apyrase in vitro and in vivo, as well as targ-CD39 and as a control, nontarg-CD39 in vivo.
MEASUREMENTS AND MAIN RESULTS: Under conditions of sepsis, agents with nucleoside triphosphate hydrolase activity decreased platelet-leukocyte-endothelium interaction, transcription of pro-inflammatory cytokines, microvascular platelet-neutrophil aggregate sequestration, activation marker expression on platelets and neutrophils contained in these aggregates, leukocyte extravasation, and organ damage. Targ-CD39 had the strongest effect on these variables and retained hemostasis in contrast to nontarg-CD39 and potato apyrase. Most importantly, targ-CD39 improved survival in the cecal ligation and puncture model to a stronger extent then nontarg-CD39 and potato apyrase.
CONCLUSIONS: Targeting nucleoside triphosphate hydrolase activity (CD39) toward activated platelets is a promising new treatment concept to decrease systemic inflammation and mortality of sepsis. This innovative therapeutic approach warrants further development toward clinical application.
参考来源
- Granja T, Körner A, Glück C, et al. Targeting CD39 Toward Activated Platelets Reduces Systemic Inflammation and Improves Survival in Sepsis: A Preclinical Pilot Study. Crit Care Med. 2019. PMID: 30730441. doi:10.1097/CCM.0000000000003682
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。